Tashkin D P, Ashutosh K, Bleecker E R, Britt E J, Cugell D W, Cummiskey J M, DeLorenzo L, Gilman M J, Gross G N, Gross N J
Am J Med. 1986 Nov 14;81(5A):81-90. doi: 10.1016/0002-9343(86)90468-7.
The short- and long-term efficacy and safety of an inhaled quaternary ammonium anticholinergic agent, ipratropium bromide, and a beta agonist aerosol, metaproterenol, were compared in 261 nonatopic patients with chronic obstructive pulmonary disease (COPD). The study was a randomized, double-blind, 90-day, parallel-group trial. On three test days-one, 45, and 90-mean peak responses for forced expiratory volume in one second and forced vital capacity and mean area under the time-response curve were higher for ipratropium than for metaproterenol. Clinical improvement was noted in both treatment groups, especially during the first treatment month, with persistence of improvement throughout the remainder of the study. Side effects were relatively infrequent and generally mild; tremor, a complication of beta agonists, was not reported by any subject receiving ipratropium. These results support the effectiveness and safety of long-term treatment with inhaled ipratropium in COPD.
在261例非特应性慢性阻塞性肺疾病（COPD）患者中，比较了吸入性季铵抗胆碱能药物异丙托溴铵和β受体激动剂气雾剂间羟异丙肾上腺素的短期和长期疗效及安全性。该研究为一项随机、双盲、为期90天的平行组试验。在三个测试日（第1天、第45天和第90天），异丙托溴铵组一秒用力呼气量和用力肺活量的平均峰值反应以及时间-反应曲线下的平均面积均高于间羟异丙肾上腺素组。两个治疗组均观察到临床改善，尤其是在治疗的第一个月，并且在研究的剩余时间内改善持续存在。副作用相对较少且一般较轻；接受异丙托溴铵治疗的患者均未报告β受体激动剂的并发症震颤。这些结果支持了吸入异丙托溴铵在COPD长期治疗中的有效性和安全性。
